Results 231 to 240 of about 175,837 (263)
Some of the next articles are maybe not open access.
Dabrafenib Therapy for Advanced Melanoma
Annals of Pharmacotherapy, 2013Objective: To summarize the clinical development of dabrafenib and to highlight the clinically relevant distinct characteristics of dabrafenib in contrast to vemurafenib. Data Source: An English-language literature search of MEDLINE/PubMed (1966-June 2013), using the keywords GSK2118436, dabrafenib, vemurafenib, selective BRAF ...
Van Anh, Trinh +3 more
openaire +2 more sources
An RNA vaccine for advanced melanoma
Nature Reviews Immunology, 2020An RNA vaccine targeting tumour-associated antigens promotes T cell immunity in patients with advanced melanoma.
openaire +2 more sources
Vaccines against advanced melanoma
Clinics in Dermatology, 2013Research shows that cancers are recognized by the immune system but that the immune recognition of tumors does not uniformly result in tumor rejection or regression. Quantitating the success or failure of the immune system in tumor elimination is difficult because we do not really know the total numbers of encounters of the immune system with the ...
Tatiana, Blanchard +2 more
openaire +2 more sources
Advances in Melanoma: The Rationale for the Melanoma Nursing Initiative
Clinical Journal of Oncology Nursing, 2017This article provides an overview of this supplement, outlining the needs assessment process the Melanoma Nursing Initiative (MNI) used to determine the immunotherapy and targeted therapy topics for discussion as well as the process for developing the consensus statements.
openaire +2 more sources
Recent advances in melanoma research
Frontiers in Bioscience, 2006At the end of the last decade, sporadic melanomas were still considered a genetic black box. Fortunately, in the last few years the box has been opened bringing to light melanoma-relevant oncogenes, aberrant signal transduction pathways, critical alterations in the melanoma cell cycle that go beyond p16INK4a, and melanoma- microenvironment interactions
Jon A, Reed, Estela E, Medrano
openaire +2 more sources
Research progress in advanced melanoma
Cancer Letters, 2017Melanoma is a malignant tumor with high rate of metastasis and poor prognosis. How melanoma develops and how to treat it will continue to be a hot topic. This review briefly summarizes the mechanism of melanoma development and the latest progress in its treatment.
Cong, Luo, Jiayu, Shen
openaire +2 more sources
Chemotherapy for advanced malignant melanoma
International Journal of Clinical & Laboratory Research, 1992Systemic chemotherapy for the treatment of metastatic melanoma remains disappointing. Nor new single agent has demonstrated promising results. The combination of cisplatin, decarbazine, carmustine, and tamoxifen appears to be one of the most active regimens with an overall response rate approaching 50%. In some patients, responses have been durable and
A C, Buzaid, J, Murren
openaire +2 more sources
Surgical Treatment of Advanced Melanoma
Clinics in Plastic Surgery, 2010Primary surgical treatment should be considered for patients with metastatic melanoma. Because of the poor response of melanoma to chemotherapy or radiation therapy, surgery can be the best approach to quickly eliminate detectable disease and return the patient to normal activities.
openaire +2 more sources
Trametinib for patients with advanced melanoma
The Lancet Oncology, 2012Gerald Falchook and colleagues show clinical activity of the MEK inhibitor trametinib in patients with either BRAF-mutant or wild-type melanoma. Recently, two essential topics for melanoma have been reported: hepatocyte growth factor (HGF)-dependent resistance to therapy and new driver mutations in melanoma.
Shigeo, Masuda +1 more
openaire +2 more sources
Cellular Therapy for Advanced Melanoma
Surgical Clinics of North AmericaCellular therapy has been an evolving therapeutic approach in advanced melanoma over the past 40 y. The first tumor infiltrating lymphocyte (TIL) therapy, lifileucil, was Food and Drug Administration-approved in 2024 for patients with metastatic melanoma who have previously been treated with an anti-PD-1 therapy and BRAF inhibitor (BRAF V600 mutant ...
Jacob, Zaemes, Geoffrey T, Gibney
openaire +2 more sources